In a world beset by uncertain economic prospects, stronger innovation performance is essential to boosting productivity growth and job creation, and to addressing global challenges like climate change, pandemics and ageing populations. But how do we make innovation happen?
The OECD Committee for Scientific and Technological Policy is holding a Ministerial level meeting in Daejeon, Korea on 20-21 October 2015.
Les pays doivent investir davantage dans la R D à long terme, afin de développer les technologies de pointe qui façonneront l’industrie, la santé et les communications de demain, et fournir d’urgence les solutions nécessaires pour affronter les défis mondiaux tels que le changement climatique, selon une nouvelle étude de l’OCDE.
Thanks to robust skills and investment in R&D, Korea is leading in the development of frontier technologies with potential to transform production processes, stimulate the entry of new firms, and the launch of ground-breaking products and applications, according to a new OECD report.
Through this page you are able to access consensus documents that comprise technical information for use during the regulatory assessment of products of biotechnology and are intended to be mutually recognised among OECD Member countries.
All countries are investing in health data. There are however significant cross-country differences in data availability and use. Some countries stand out for their innovative practices enabling privacy-protective data use while others are falling behind with insufficient data and restrictions that limit access to and use of data, even by government itself. Countries that develop a data governance framework that enables privacy-protective data use will not only have the information needed to promote quality, efficiency and performance in their health systems, they will become a more attractive centre for medical research. After examining the current situation in OECD countries, a multi-disciplinary advisory panel of experts identified eight key data governance mechanisms to maximise benefits to patients and to societies from the collection, linkage and analysis of health data and to, at the same time, minimise risks to the privacy of patients and to the security of health data. These mechanisms include coordinated development of high-value, privacy-protective health information systems, legislation that permits privacy-protective data use, open and transparent public communication, accreditation or certification of health data processors, transparent and fair project approval processes, data de-identification and data security practices that meet legal requirements and public expectations without compromising data utility and a process to continually assess and renew the data governance framework as new data and new risks emerge.
This document gives a recommendations on the Use of Assessment Factors for Intra- and Interspecies Differences in Human Health Risk Assessment of Nanomaterials.
OECD major events and activities relating to biotechnologies: latest developments are updated biannually in this Newsletter.
La République tchèque se distingue depuis longtemps par sa capacité d’innovation et sa créativité. Après tout, elle est la patrie de l’écrivain Karel Čapek, qui a inventé le mot « robot » en 1921. Soixante-dix ans plus tard, Jan et Zdenak Sverak définissaient la créativité tchèque dans leur film L’École élémentaire, nominé aux Oscars, à travers le personnage du bricoleur sachant tout faire, tout réparer.
Engineered nano-objects and their agglomerates and aggregates are handled today in workplaces that span broad occupational environments. The three-tiered approach described in this document is not intended to be a risk assessment strategy, but part of a risk management and mitigation strategy.